دورية أكاديمية
أعرض في EDS

Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.

التفاصيل البيبلوغرافية
العنوان: Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
المؤلفون: Corsten CEA; MS Center ErasMS, Department of Neurology, Erasmus MC Rotterdam, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands., Huygens SA; Huygens & Versteegh, Zwijndrecht, the Netherlands., Versteegh MM; Huygens & Versteegh, Zwijndrecht, the Netherlands., Wokke BHA; MS Center ErasMS, Department of Neurology, Erasmus MC Rotterdam, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands., Smets I; MS Center ErasMS, Department of Neurology, Erasmus MC Rotterdam, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. Electronic address: i.smets@erasmusmc.nl., Smolders J; MS Center ErasMS, Department of Neurology, Erasmus MC Rotterdam, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands; Department of Immunology, Erasmus MC Rotterdam, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. Electronic address: j.j.f.m.smolders@erasmusmc.nl.
المصدر: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2023 Dec; Vol. 80, pp. 105100. Date of Electronic Publication: 2023 Oct 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-0356 (Electronic) Linking ISSN: 22110348 NLM ISO Abbreviation: Mult Scler Relat Disord Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B. V.
مواضيع طبية MeSH: Sphingosine 1 Phosphate Receptor Modulators*/pharmacology , Sphingosine 1 Phosphate Receptor Modulators*/therapeutic use , Multiple Sclerosis, Relapsing-Remitting*/drug therapy, Humans ; Fingolimod Hydrochloride/therapeutic use ; Sphingosine-1-Phosphate Receptors ; Immunologic Factors ; Recurrence ; Cost-Benefit Analysis ; Immunosuppressive Agents
مستخلص: Background: Three sphingosine-1-phosphate receptor (S1PR) modulators are currently available as disease-modifying therapies (DMTs) for relapsing MS in the Netherlands (i.e. fingolimod, ozanimod and ponesimod). We aimed to identify which S1PR modulator yields the highest benefit from a health-economic and societal perspective during a patient's lifespan.
Methods: Incorporating Dutch DMT list prices, we used the ErasmusMC/iMTA MS model to compare DMT sequences, including S1PR modulators and eight other DMT classes, for treatment-naïve patients with relapsing MS in terms of health outcomes (number of lifetime relapses, time to Expanded Disability Status Scale (EDSS) 6, lifetime quality-adjusted life years (QALYs)) and cost-effectiveness (net health benefit (NHB)). We estimated the influence of list price and EDSS progression on cost-effectiveness outcomes.
Results: In deterministic and probabilistic analysis, DMT sequences with ponesimod have lower lifetime costs and higher QALYs resulting in a higher average NHB compared to sequences with other S1PR modulators. Ponesimod remains the most cost-effective S1PR modulator when EDSS progression is class-averaged. Given the variable effects on disability progression, list price reductions could make fingolimod but not ozanimod more cost-effective than ponesimod.
Conclusion: Our model favours ponesimod among the S1PR modulators for the treatment of relapsing MS. This implies that prioritizing ponesimod over other S1PR modulators translates into a more efficacious spending of national healthcare budget without reducing benefit for people with MS. Prioritizing cost-effective choices when counselling patients contributes to affordable and accessible MS care.
Competing Interests: Declaration of Competing Interest Cato E.A. Corsten and Beatrijs H.A. Wokke declare no conflicts of interest. Simone A. Huygens and Matthijs M. Versteegh are shareholders of Huygens & Versteegh which conducts research for government organizations and pharmaceutical companies, including research in MS. Ide Smets has received honoraria from Merck and Biogen Idec. Joost Smolders received lecture and/or consultancy fee from Biogen, Merck, Novartis, and Sanofi Genzyme.
(Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
فهرسة مساهمة: Keywords: Cost-effectiveness; Disease-modifying therapy; Health economics; Relapsing remitting multiple sclerosis; Sphingosine-1-phosphate receptor modulators; Treatment sequence
المشرفين على المادة: G926EC510T (Fingolimod Hydrochloride)
0 (Sphingosine 1 Phosphate Receptor Modulators)
5G7AKV2MKP (ponesimod)
0 (Sphingosine-1-Phosphate Receptors)
0 (Immunologic Factors)
0 (Immunosuppressive Agents)
تواريخ الأحداث: Date Created: 20231109 Date Completed: 20231222 Latest Revision: 20231222
رمز التحديث: 20231222
DOI: 10.1016/j.msard.2023.105100
PMID: 37944195
قاعدة البيانات: MEDLINE
الوصف
تدمد:2211-0356
DOI:10.1016/j.msard.2023.105100